Abstract 4281
Background
Ultrasound is the first and primary breast screening for thoes women with small and dense breast and is superior to mammography. BI-RADS using ultrasound causes approxinately over 40%-60% false-positive results, unnecessary biopsy and relatively low cancer-to biosy rate. This multi-center study in China is to determine whether contrast-enhanced ultrasound (CEUS) of the breast can improve the precision of BI-RADS.
Methods
1721 patients were enrolled at 8 sites in China. CEUS was performed before core needle biopsy or surgical resection and a revised BI-RADS classification was assigned based on CEUS performance. Using pathological results as golden standerd to evaluate the diagnostic performance of CEUS-based BI-RADS.
Results
1738 solid breast lesions (5.0-39.8mm, 17.89± 8.65mm) classified as BI-RADS 4 or 5 on conventional ultrasound or mammography. 771/1738(44.36%) are malignant and 967/1738(55.64%) are benign. The CEUS-based BI-RADS evaluation classified 402/1738 (23.13%) lesions into category 3 and its accuracy, sensitivity, specificity, positive and negative predictive values of 65.0%, 97.0%, 40.0%, 56.0% and 94.0%. The cancer-to-biopsy yield was 57.71% with CEUS-based BI-RADS 3 selected as the biopsy threshold compared with 44.36% otherwise, while the total biopsy rate was only 76.87% compared with 100% otherwiseand will reduce 39.5% (382/967) unnecessary biopsy rate in those benign nodules. Overall, only 2.59% of invasive cancers were misdiagnosed similar as BI-RADS 3 we use nowadays.
Conclusions
This study suggests that evaluation of BI-RADS 4 or 5 breast lesions with CEUS result in reduced biopsy rates and increased cancer-to-biopsy yields.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jun Luo.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2671 - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
Presenter: Ayako Nakashoji
Session: Poster Display session 3
Resources:
Abstract
2650 - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer
Presenter: Sun-Ae Park
Session: Poster Display session 3
Resources:
Abstract
1462 - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
Presenter: Lisha Ying
Session: Poster Display session 3
Resources:
Abstract
5787 - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.
Presenter: Raimondo Di Liello
Session: Poster Display session 3
Resources:
Abstract
5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Dimitris Mavroudis
Session: Poster Display session 3
Resources:
Abstract
5286 - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Presenter: Silvia Calabuig-Fariñas
Session: Poster Display session 3
Resources:
Abstract
5781 - Exosomes in NSCLC as a source of biomarkers
Presenter: Elena Duréndez
Session: Poster Display session 3
Resources:
Abstract
1447 - The role of Pim-1 in the development and progression of papillary thyroid carcinoma
Presenter: Xin Zhu
Session: Poster Display session 3
Resources:
Abstract
1323 - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 3
Resources:
Abstract
3290 - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling
Presenter: Josef Srovnal
Session: Poster Display session 3
Resources:
Abstract